Actinogen Medical (ASX:ACW) ROCE %: -165.63% (As of Dec. 2025)


What is Actinogen Medical ROCE %?

Actinogen Medical ASX:ACW +1.52% ROCE % is -165.63% as of Dec. 2025. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Actinogen Medical's annualized ROCE % for the quarter that ended in Dec. 2025 was -165.63%.

Actinogen Medical  (ASX:ACW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Actinogen Medical ROCE % Related Terms

Actinogen Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Actinogen Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinogen Medical ROCE % Chart

Actinogen Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.02 -48.06 -60.94 -78.05 -76.32

Actinogen Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -181.93 -18.46 -73.83 -61.20 -165.63

Actinogen Medical ROCE % Calculation

Actinogen Medical's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-14.683/( ( (21.312 - 1.357) + (24.481 - 5.959) )/ 2 )
=-14.683/( (19.955+18.522)/ 2 )
=-14.683/19.2385
=-76.32 %

Actinogen Medical's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-22.388/( ( (24.481 - 5.959) + (10.601 - 2.09) )/ 2 )
=-22.388/( ( 18.522 + 8.511 )/ 2 )
=-22.388/13.5165
=-165.63 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -165.63% mean?
Actinogen Medical (ASX:ACW) has a ROCE % of -165.63% as of Dec. 2025.
Is Actinogen Medical's ROCE % too high?
Actinogen Medical's current ROCE % is -165.63%.
How does Actinogen Medical's ROCE % compare to VRTX and REGN?
Actinogen Medical's ROCE % of -165.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Actinogen Medical's current ROCE % is -165.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinogen Medical stock overvalued right now?
Actinogen Medical (ASX:ACW) has a current ROCE % of -165.63%. The current ROCE % is -165.63%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Actinogen Medical (ASX:ACW), the current ROCE % is -165.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinogen Medical Business Description

Other Exchanges ATGGF:USA3AC:Germany
Address 109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.